Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Analytical Method Development: SOP for Sterility Testing Method for Ophthalmic Products – V 2.0

Posted on By

Analytical Method Development: SOP for Sterility Testing Method for Ophthalmic Products – V 2.0

Standard Operating Procedure for Sterility Testing Method of Ophthalmic Products in Analytical Method Development


Department Analytical Method Development
SOP No. SOP/AMD/248/2025
Supersedes SOP/AMD/248/2022
Page No. Page 1 of 13
Issue Date 21/05/2025
Effective Date 23/05/2025
Review Date 21/05/2026

1. Purpose

To describe the procedure for performing sterility testing of ophthalmic products using the membrane filtration and direct inoculation methods, ensuring products are free from viable

microorganisms as per pharmacopeial requirements.

2. Scope

This SOP applies to Analytical Method Development (AMD) and Quality Control (QC) departments involved in testing ophthalmic formulations including eye drops, ointments, and gel-based sterile products.

3. Responsibilities

  • Microbiology Analyst: Performs sterility test procedures, records observations, and maintains aseptic conditions.
  • QC Analyst: Assists in sample preparation and documentation.
  • QA Executive: Reviews and approves sterility test results, deviations, and trend reports.
See also  Analytical Method Development: SOP for Analytical Method for Liposomes - V 2.0

4. Accountability

The Head of Analytical Method Development is accountable for ensuring that sterility testing is performed in compliance with USP <71>, EP 2.6.1, and WHO TRS guidelines.

5. Procedure

5.1 Selection of Method

  1. Use membrane filtration method for aqueous ophthalmic solutions.
  2. Use direct inoculation method for viscous/semi-solid ophthalmic products (e.g., gels or ointments).

5.2 Environmental and Equipment Conditions

  1. Perform testing under aseptic conditions in a certified Grade A laminar airflow hood located in Grade B cleanroom.
  2. Use sterilized equipment including filtration units, forceps, scissors, and media bottles.

5.3 Media Preparation

  1. Use Fluid Thioglycollate Medium (FTM) for anaerobic and aerobic bacteria.
  2. Use Soybean Casein Digest Medium (SCDM or TSB) for fungi and aerobic bacteria.
  3. Perform growth promotion testing (GPT) using standardized organisms before use.

5.4 Membrane Filtration Method

  1. Filter prescribed quantity (usually 10 mL) of ophthalmic product through 0.45 µm membrane filter using sterile filtration assembly.
  2. Rinse filter with sterile fluid (e.g., Fluid A or Fluid D) to remove preservatives or antimicrobial agents.
  3. Transfer one membrane into FTM and another into SCDM using sterile forceps.
  4. Incubate FTM at 30–35°C and SCDM at 20–25°C for 14 days.
See also  Analytical Method Development: Determination of Absorptivity Values - V 2.0

5.5 Direct Inoculation Method

  1. Inoculate required volume (typically 0.2–1 mL or 200 mg) of ophthalmic ointment or gel into each medium.
  2. Swirl gently to disperse; incubate as described in 5.4.

5.6 Observation and Interpretation

  1. Check test media daily for turbidity or visible microbial growth.
  2. If no growth observed after 14 days, report as “Sterile.”
  3. If growth is observed, perform microbial identification and root cause analysis.

5.7 Validation and Controls

  1. Validate neutralization of antimicrobial agents before routine testing.
  2. Include positive controls (challenge microorganisms) and negative controls (uninoculated media).

6. Abbreviations

  • FTM: Fluid Thioglycollate Medium
  • SCDM: Soybean Casein Digest Medium
  • GPT: Growth Promotion Test
  • USP: United States Pharmacopeia
  • EP: European Pharmacopeia

7. Documents

  1. Sterility Test Log – Annexure-1
  2. Environmental Monitoring Report – Annexure-2
  3. Growth Promotion Certificate – Annexure-3

8. References

  • USP <71>: Sterility Tests
  • EP 2.6.1: Sterility
  • WHO TRS 961 Annex 6: Good Manufacturing Practices for Sterile Products

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name Dr. Ruchi Sharma Amol Khedekar Sunita Reddy
Designation Microbiologist QA Reviewer Head – AMD
Department Analytical Method Development QA Analytical Method Development

11. Annexures

Annexure-1: Sterility Test Log

Sample ID Method Media Used Volume Tested Incubation Period Result
OPH-2025-001 Membrane Filtration FTM, SCDM 10 mL 14 Days Sterile

Annexure-2: Environmental Monitoring Report

Date Area Airborne Particulates Surface CFU Personnel Monitoring Status
20/05/2025 Grade A LAF Nil 1 CFU Nil Pass

Annexure-3: Growth Promotion Certificate

Media lots used for this test were challenged with ATCC strains of Staphylococcus aureus, Bacillus subtilis, Aspergillus brasiliensis, Clostridium sporogenes, and Candida albicans. All media supported visible growth within 5 days.

Revision History:

Revision Date Revision No. Details Reason Approved By
21/05/2025 2.0 Added environmental monitoring and validation criteria for neutralization Annual Review and GMP Compliance Sunita Reddy
01/03/2022 1.0 Initial SOP Release New SOP QA Head
See also  Analytical Method Development: Thermal Stability Analysis using GC - V 2.0
Analytical Method Development V 2.0 Tags:Analytical Method Development SOP, SOP for analytical calculations, SOP for analytical documentation, SOP for analytical instrument calibration, SOP for analytical instrument qualification, SOP for analytical method change control, SOP for analytical method deviation handling, SOP for analytical method documentation practices, SOP for analytical method lifecycle management, SOP for analytical method optimization, SOP for analytical method risk assessment, SOP for analytical method training and competency, SOP for analytical method transfer protocol, SOP for analytical method validation, SOP for forced degradation studies, SOP for HPLC method development, SOP for limit of detection (LOD) determination, SOP for limit of quantitation (LOQ) determination, SOP for method accuracy testing, SOP for method linearity assessment, SOP for method precision evaluation, SOP for method reproducibility, SOP for method robustness testing, SOP for method transfer, SOP for method verification, SOP for qualification of working standards, SOP for reference standard handling, SOP for specificity testing in analytical methods, SOP for stability indicating methods, SOP for system suitability testing

Post navigation

Previous Post: Biosimilars: SOP for Reduction and Alkylation (if applicable) – V 2.0
Next Post: Elixir Department: SOP for Cleaning Low Volume Transfer Hoses – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2026 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version